Summary A retrospective and a prospective trial were carried out in patients with malignant melanomas to investigate the predictive value of an in vitro chemosensitivity assay based on the Courtenay and Mills soft agar cultivation method. Evaluable in vitro chemosensitivity data for the three agents DTIC, CCNU, and vinblastine were obtained in 153 cases. In the retrospective study in which the patients received chemotherapy without prior knowledge of the test results, 50 in vitro/in vivo correlations (40 patients) were made, and in the prospective study, where patients received the single agent most active in vitro, 55 correlations (45 patients) were performed. In both studies the sensitivity of the test (the ability to identify patients who will respond to chemotherapy) was 100% and the specificity (the ability to identify patients who will not respond) was 87-98%. Depending on whether 'no change' and 'mixed response' were classified as sensitivity or resistance, the predictive value of a negative test was -100% and that of a positive test 37.5-87.5%. The response rate was low in both series, and although it was somewhat higher in the prospective than in the retrospective trial, the difference was not significant. The median survival time was not significantly different in the two treatment series. We conclude that the chemosensitivity assay here used is reliable and has predictive value, but that the chemotherapeutic agents currently available for treatment of melanoma are too ineffective to -warrant routine use of the assay in this disease.
During the last decade, starting with the pioneer work of Salmon et al., (1978) , a large number of laboratories have attempted to use chemosensitivity testing in vitro, based on semi-solid medium, as a guide to the treatment of various human malignant tumours. Several interesting reports on the predictive value of such tests in various human tumours have appeared. Although the initial enthusiasm for predictive testing has declined, such testing may be useful in certain types of cancer (Alberts et al., 1984; Welander et al., 1984; Hanauske et al., 1985) and the prediction concept has prompted valuable basic and clinically relevant studies of cell biology and therapy responses in vitro.
Malignant melanomas lend themselves to chemosensitivity testing insofar as they are rather easy to grow in semi-solid medium, and several reports on predictive chemosensitivity testing in this tumour type have appeared. Positive correlations between in vitro sensitivity and clinical response have been reported, but a beneficial value of the test systems in the routine chemotherapy of patients has not been established (Meyskens et al., 1981 (Meyskens et al., , 1984 Bertelsen et al., 1984; Mackie et al., 1984; Tveit et al., 1982 Tveit et al., , 1985 . Here we report on our experience in a retrospective and prospective trial of malignant melanoma using a cultivation method different from that used by most workers, and also a different calibration method of the in vitro results.
Materials and methods

Tumours
Altogether 402 histologically verified malignant melanomas (metastases or local recurrences), surgically removed from patients admitted to The Norwegian Radium Hospital, were disaggregated by a mechanical procedure employing a stomacher (Tveit et al., 1984 (Tveit et al., 1984 Clinical treatment In the retrospective trial the patients received single-agent DTIC, CCNU or vinblastine treatment, chosen by the clinician without prior knowledge of the in vitro test results on tumour specimens. In the prospective study the clinician waited for the in vitro testing and treated the patient with the one of the three agents that was most active in vitro (see below). In both studies, DTIC was used at a dosage of 800 mg m -2, given every 4 weeks, CCNU at a dosage of 120mgm-2 given every 6 weeks, and vinblastine at 6 mg m-2 given every week. Response evaluation was performed after 2 to 3 months by simple measurements of palpable lesions, chest X-rays or CT-scans.
Clinical responses were classified according to international criteria as complete response (CR), partial response (PR) and progressive disease (PD). In addition, mixed response (MR) was defined as more than 50% regression of one or more metastases, while concurrently one or more lesions increased in size or a new one appeared during treatment. No change (NC) was defined as lack of progression of any tumour manifestation for at least 3 months after prior progression. 
Data analysis
The in vitro chemosensitivity was quantitated on the basis of the observed dose-response curves. The ID50s (doses required to inhibit colony formation by 50%) were derived from the dose-response curves and correlated with the in vivo sensitivity of melanoma xenografts previously measured (Tveit et al., 1980 (Tveit et al., , 1982 . By this calibration procedure the in vitro chemosensitivity is converted to an in vivo sensitivity and is expressed in terms of expected growth delay (EGD).
In our earlier studies (Tveit, 1983) , we found that an EGD limit of 2.0 was a useful cut-off value for predicting tumours as being either 'sensitive' or 'resistant' in vivo. 'Sensitivity' of the test system was defined as the ability of the assay to identify patients who will respond to chemotherapy and 'specificity' as its ability to identify patients who will not respond to chemotherapy. These parameters were expressed as follows: Sensitivity = sS/(sS+ rS), and specificity = rR/(rR + sR), where s and S denote sensitivities in vitro and in the clinic, respectively, and r and R resistance in vitro and in the clinic, respectively. Moreover, the 'predictive value of a positive test' (PV+) was defined as sS/(sS+sR) and the 'predictive value of a negative test' as rR/(rR+rS).
Results
Altogether 402 malignant melanomas were cultivated in soft agar and gave evaluable colony formation in vitro. Two hundred and eighty-five tumours (71%) formed more than 10 colonies and the colony forming efficiencies obtained ranged from 0.15% up to 20%. Sensitivity testing for DTIC, CCNU and vinblastine was performed in 240 cases, and in 153 cases of these (64%), evaluable chemosensitivity data were obtained for all 3 drugs. In 85 patients, 105 correlations between in vitro data and evaluable clinical responses were made. Figure 1 shows representative dose-response relationships for 10 tumours treated in vitro with DTIC, CCNU and vinblastine. It is gratifying that none of the dose-response curves had plateaus. The ID50s were derived graphically and converted to EGD values as described in the Materials and methods section and in Tveit et al., (1980) . In general, the same chemosensitivity patterns were found in metastases compared to local recurrences.
In the retrospective study, 3 partial responses were observed and in addition 4 patients had no change or mixed response. In 43 cases progressive disease was found. In the prospective study, one patient had complete response, 8 had partial response, 6 had no change or mixed response and 40 had progressive disease. Figure 2 shows correlations between the estimated EGD values and the various categories of clinical responses in the retrospective study (50 cases) and in the prospective study (55 cases). (Table II) . If MR and NC are classified as clinical resistance, in the retrospective study the sensitivity was 100%, the specificity 89%, the predictive value of a positive test (PV+) was 38%, and the predictive value of a negative test (PV-) 100%. If, however, MR and NC are classified as clinical sensitivity, the specificity and PV + values increase (Table II) . In the prospective study, the sensitivity and PV-were 100% if MR and NC are classified as resistance. The specificity was 87% and PV+ was 60%. If MR+NC are classified as sensitive, the consequence is that the sensitivity and PVvalues decrease, and the specificity and PV + values increase. In the prospective study, it turned out that DTIC was most active in 32, CCNU in 14, and vinblastine in 9 of the 55 cases. These findings parallel closely the clinical experience that DTIC is the most active agent in melanomas, more active than CCNU and vinblastine. The results show that relatively more objective clinical responses were obtained in the prospective than in the retrospective study. Thus, PR+CR increased from 6.0% in the retrospective study to 16.4% in the prospective study (not statistically significant, P= 0.09, Chi-square test), and NC + MR increased from 8.0% to 10.8%. Altogether, 27.2% of the patients in the prospective study had some kind of response, compared to 14.0% in the retrospective study (P=0.09).
The median survival was not significantly different in the two trials (7.3 months in the retrospective and 9.1 months in the prospective trial).
Discussion
Several significant facts emerge from the present study. In the first place, the association between in vitro sensitivity and clinical response was highly significant. This shows that the assay here used, which is based on the Courtenay and Mills culture method and calibrated by means of melanoma xenografts, is reliable and has high predictive value. Secondly, the response rate to the agents tested, considered by most workers to be among the most efficacious ones in melanoma, was very low. Although the response rate was higher in the prospective than in the retrospective study, the difference was not statistically significant, and the median survival was not significantly higher in the prospective trial. Thus, our study fails to demonstrate a definite therapeutic value of predictive testing in malignant melanoma. A serious shortcoming of in vitro chemosensitivity testing is the low percentage of evaluable tests (von Hoff et al., 1981) . In 240 of the 402 specimens received in the laboratory, a sufficient number of cells was obtained to set up a test with the 3 different agents at 4 different concentr.ations. Sixty-four per cent of these experiments could be evaluated for chemosensitivity to all agents. This implies that in the majority (62%) of the malignant melanoma specimens received, chemosensitivity data could not be obtained, either due to an insufficient number of cells in the specimen, or to inadequate growth. We do not believe that these figures can be significantly improved as we have made considerable efforts to optimize both the disaggregation and the cultivation procedures (Tveit et al., 1984) .
Although the probability of finding a drug capable of inducing a response undoubtedly will increase with increasing number of drugs tested, as shown by Meyskens et al. (1981) , such extended testing will be possible only in a minority of cases, and we doubt that the increase in effort and expense required will be justified by the results. Thus, in several cases we have performed testing with 6 different agents without finding any of them active (not shown), and we believe that many cases of malignant melanomas may be resistant to all agents currently available.
In spite of the low response rate of melanoma to current chemotherapy, many centres continue to administer chemotherapy routinely to melanoma patients with metastatic disease. A rationale for using a predictive assay in a tumour type such as malignant melanoma, could be to identify the few tumours that are sensitive and to avoid chemotherapy in the majority of patients who have unresponsive tumours. However, in view of the marginal effect of all available chemotherapy regimens with only minor or partial responses of short duration without any prolongation of survival time, we conclude that a routine testing of patients with malignant melanomas is not justified at the present time. This situation may change if more active agents become available. Presently, melanoma patients should, in our opinion, not have chemotherapy with any of the current cytotoxic agents, but should preferably be included in clinical Phase II protocols of promising new agents. 
